子宫内膜癌:使用2020年ESGO-ESTRO-ESP风险分层系统分析复发模式和现实生活结果数据
R Karkia1, T R Nyakunengwa2, C Uwins1
1Academic Department of Gynaecological Oncology, Royal Surrey NHS Foundation Trust, Surrey, UK.
概括
2020年ESGO-ESTRO-ESP风险分层系统准确预测子宫内膜癌复发和存活率. 遵循当前的指导方针可以改善患者的治疗结果,尤其是在早期的疾病中.
科学领域:
- 妇科瘤学 妇科瘤学
- 癌症的分期和风险分层.
- 子宫内膜癌研究研究
背景情况:
- 自20世纪90年代以来,子宫内膜癌的发病率大幅增加.
- 预计到2035年,癌症将成为女性癌症死亡的第六大原因.
- 在早期疾病中需要准确的预后工具.
研究的目的:
- 将2018年FIGO分阶段系统与2020年ESGO-ESTRO-ESP风险分层进行比较.
- 评估子宫内膜癌的复发模式.
- 评估早期疾病的分期系统之间的预后差异.
主要方法:
- 对692名患者 (2010-2017年) 的回顾性队列研究.
- 卡普兰-梅尔对整体存活率 (OS) 和无复发存活率 (RFS) 的生存分析.
- 考克斯回归和千平方测试用于预后因素和复发模式.
主要成果:
- 复发率为14.9%,复发的中位时间为17.1个月.
- 低风险和高风险组之间的OS和RFS显著差异 (p < 0.001).
- 根据高风险组预测的复发,淋巴血管空间入侵 (LVSI),癌和血清亚型.
结论:
- 2020年ESGO-ESTRO-ESP系统准确地分层了子宫内膜癌复发风险.
- 按照当前指导方针治疗的患者表现出明显改善的结果.
- 该系统有助于预测远期复发,与负LVSI和1级癌症相关的风险降低.
相关概念视频
Cancer Survival Analysis
342
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
342
Comparing the Survival Analysis of Two or More Groups
176
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
176


